Reyna Betances
Optometrist · Brooklyn, NYNPI 1750955779
Payments from drug & device makers
Across 152 payments — averaging $25.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$855
- Bausch & Lomb Americas Inc.$586
- Alcon$475
- AbbVie$460
- Novartis$405
- Harrow Eye, LLC$221
- plus $857 from 10 others
What the payments were for
- Food & beverage$3,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 32 | $855 |
| Bausch & Lomb Americas Inc. | 23 | $586 |
| Alcon | 20 | $475 |
| AbbVie(2 entities) | 18 | $460 |
| Novartis | 17 | $405 |
| Harrow Eye, LLC | 9 | $221 |
| Sun Pharmaceutical Industries Inc. | 10 | $212 |
| Tarsus Pharmaceuticals, Inc. | 6 | $137 |
| Eyevance Pharmaceuticals LLC | 5 | $104 |
| Glaukos Corporation | 1 | $85 |
| Johnson & Johnson Vision Care, Inc. | 1 | $77 |
| Thea Pharma Inc. | 3 | $67 |
| Dompe US, Inc. | 2 | $54 |
| Kala Pharmaceuticals, Inc. | 2 | $49 |
| Amgen | 2 | $48 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,860 in reported general payments places this provider in the 90th percentile of 2,743 optometrist providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 166 | $111,855 |
| RestasisCyclosporine | 92 | $79,614 |
| LumiganBimatoprost | 84 | $31,316 |
| TyrvayaVarenicline Tartrate | 27 | $16,724 |
| Cyclosporine | 28 | $8,202 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $6,053 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 39 | $1,494 |
| Brimonidine Tartrate | 15 | $1,284 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $749 |
| Azelastine Hcl | 47 | $565 |
| Latanoprost | 126 | $508 |
| ErythromycinErythromycin Base | 41 | $350 |
| Timolol Maleate | 28 | $272 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 24 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $586 | $111,855166 claims |
| AbbVieRestasis, Lumigan | $460 | $110,930176 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $855 | $16,72427 claims |
| AlconSimbrinza | $475 | $6,05330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,743 optometrist providers in New York.
Other optometrist in Brooklyn
- Justin BazanBrooklyn$304K
- David HoBrooklyn$100K
- Daniel EpshteinBrooklyn$43K
- Katherine MastrotaBrooklyn$14K
- Andrew SaccoVestal$1.8M
- George ZikosNew York$1M
- Roy KlineLake Katrine$822K
- Irene FrantzisNew York$663K
- Daphne AmbroseNew York$509K
- Susan ResnickNew York$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.